 | Up a level |
Ahn, Myung-Ju and Mendoza, Marvin Jonne L. and Pavlakis, Nick and Kato, Terufumi and Soo, Ross A. and Kim, Dong-Wan and Liam, Chong Kin and Hsia, Te-Chun and Lee, Chee Khoon and Reungwetwattana, Thanyanan and Geater, Sarayut and Chan, Oscar Siu Hong and Prasongsook, Naiyarat and Solomon, Benjamin J. and Nguyen, Thi Thai Hoa and Kozuki, Toshiyuki and Yang, James Chih-Hsin and Wu, Yi-Long and Kam, Tony Shu and Tan, Daniel Shao-Weng and Yatabe, Yasushi (2022) Asian Thoracic Oncology Research Group (ATORG) expert consensus statement on MET alterations in NSCLC: Diagnostic and therapeutic considerations. CLINICAL LUNG CANCER, 23 (8). pp. 670-685. ISSN 1938-0690, DOI https://doi.org/10.1016/j.cllc.2022.07.012.
Park, Keunchil and Janne, Pasi A. and Kim, Dong-Wan and Han, Ji-Youn and Wu, Ming-Fang and Lee, Jong-Seok and Kang, Jin-Hyoung and Lee, Dae Ho and Cho, Byoung Chul and Yu, Chong-Jen and Pang, Yong Kek and Felip, Enriqueta and Kim, Hyunjin and Baek, Eunhye and Noh, Young Su (2021) Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study. Cancer, 127 (9). pp. 1407-1416. ISSN 0008-543X, DOI https://doi.org/10.1002/cncr.33385.
